Browsing: Ensartinib

Survivors

Ensartinib Treatment for Rare Nonclassical ALK Fusion Lung Adenocarcinoma With Brain Metastasis

By NewsCancerSeptember 10, 20260

IntroductionALK rearrangements constitute a clinically important molecular subtype of non–small cell lung cancer (NSCLC), particularly lung adenocarcinoma, occurring in approximately…

Support

Adjuvant Ensartinib Improves DFS in Resected ALK-Positive NSCLC

By NewsCancerJuly 27, 20260

Adjuvant ensartinib (Ensacove) significantly improved disease-free survival (DFS) vs placebo in patients with completely resected, ALK-positive stage IB to IIIB…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

The Tattoo That Marks 13 Years of Healing After Abuse

Communicating CAR T Secondary Malignancy Risks in Hematologic Oncology

Treatment Strategies for Biomarker-Negative and PI3K-Pathway Altered HR+/HER2− mBC

Browsing: Ensartinib

Ensartinib Treatment for Rare Nonclassical ALK Fusion Lung Adenocarcinoma With Brain Metastasis

Adjuvant Ensartinib Improves DFS in Resected ALK-Positive NSCLC

The Tattoo That Marks 13 Years of Healing After Abuse

Communicating CAR T Secondary Malignancy Risks in Hematologic Oncology

Treatment Strategies for Biomarker-Negative and PI3K-Pathway Altered HR+/HER2− mBC

Ketone signaling goes nuclear | Nature Chemical Biology

The Tattoo That Marks 13 Years of Healing After Abuse

Communicating CAR T Secondary Malignancy Risks in Hematologic Oncology

Treatment Strategies for Biomarker-Negative and PI3K-Pathway Altered HR+/HER2− mBC

Ketone signaling goes nuclear | Nature Chemical Biology

Latest Post

The Tattoo That Marks 13 Years of Healing After Abuse

Communicating CAR T Secondary Malignancy Risks in Hematologic Oncology

Treatment Strategies for Biomarker-Negative and PI3K-Pathway Altered HR+/HER2− mBC

Subscribe to Updates

What's Hot

Browsing: Ensartinib